Literature DB >> 17655696

Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk.

Leon J Worth1, Karin A Thursky, John F Seymour, Monica A Slavin.   

Abstract

BACKGROUND: Vancomycin-resistant enterococci (VRE) are significant nosocomial pathogens in patients with hematologic malignancy. Identification of risk factors for infection is necessary for targeted prevention and surveillance. OBJECTIVES AND METHODS: An outbreak of VRE infection occurred at a tertiary cancer hospital between 1 August 2003 and 30 June 2005. Infection control measures recommended by the Society for Healthcare Epidemiology of America were used throughout the outbreak period. A matched case-control study was performed to identify risk factors for VRE infection.
RESULTS: Fourteen VRE infections (13 episodes of bacteremia, one urinary tract infection) occurred a median of 10.5 d following hospital admission. All were due to Enterococcus faecium vanB. Univariate analysis identified the following variables to be significantly associated with VRE infection: presence of neutropenia, neutropenia >or=7 d, underlying diagnosis of acute myeloid leukemia (AML), and receipt of vancomycin, metronidazole or carbapenem antibiotic therapy in the 30 d prior to infection. On multivariate analysis, an underlying diagnosis of AML [odds ratio (OR), 15.00; P = 0.017] and vancomycin therapy during the previous 30 d (OR, 17.96; P = 0.036) were retained as independent risk factors for infection.
CONCLUSIONS: Risk stratification for development of VRE infection is possible for patients with hematologic malignancy. Patients with AML represent a high-risk population, and targeted prevention strategies must include improved antibiotic stewardship, particularly judicious use of vancomycin therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17655696     DOI: 10.1111/j.1600-0609.2007.00911.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  21 in total

1.  Development of a Real-Time PCR Protocol Requiring Minimal Handling for Detection of Vancomycin-Resistant Enterococci with the Fully Automated BD Max System.

Authors:  Alexander H Dalpke; Marjeta Hofko; Stefan Zimmermann
Journal:  J Clin Microbiol       Date:  2016-06-29       Impact factor: 5.948

2.  Comparative study of selective chromogenic (chromID VRE) and bile esculin agars for isolation and identification of vanB-containing vancomycin-resistant enterococci from feces and rectal swabs.

Authors:  E A Grabsch; S Ghaly-Derias; W Gao; B P Howden
Journal:  J Clin Microbiol       Date:  2008-10-01       Impact factor: 5.948

Review 3.  The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Authors:  Ying Taur; Eric G Pamer
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

4.  The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Authors:  Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

5.  Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model.

Authors:  Margot Fijlstra; Mithila Ferdous; Anne M Koning; Edmond H H M Rings; Hermie J M Harmsen; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2014-11-08       Impact factor: 3.603

6.  Evaluation of a chromogenic agar under development to screen for VRE colonization.

Authors:  George Kallstrom; Christopher D Doern; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

7.  Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.

Authors:  Ajay Gupta; Mansher Singh; Harkirat Singh; Lalit Kumar; Atul Sharma; Sameer Bakhshi; Vinod Raina; Sanjay Thulkar
Journal:  Med Oncol       Date:  2009-10-15       Impact factor: 3.064

8.  Improved detection of vanB2-containing enterococcus faecium with vancomycin susceptibility by Etest using oxgall supplementation.

Authors:  E A Grabsch; K Chua; S Xie; J Byrne; S A Ballard; P B Ward; M L Grayson
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

Review 9.  The prevention and management of infections due to multidrug resistant organisms in haematology patients.

Authors:  Jason A Trubiano; Leon J Worth; Karin A Thursky; Monica A Slavin
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 10.  Control of the spread of vancomycin-resistant enterococci in hospitals: epidemiology and clinical relevance.

Authors:  Nico T Mutters; Volker Mersch-Sundermann; Reinier Mutters; Christian Brandt; Wulf Schneider-Brachert; Uwe Frank
Journal:  Dtsch Arztebl Int       Date:  2013-10-25       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.